Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1998;98:2223-2226

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Apstein, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apstein, C. S.

(Circulation. 1998;98:2223-2226.)
© 1998 American Heart Association, Inc.


Editorials

Glucose-Insulin-Potassium for Acute Myocardial Infarction

Remarkable Results From a New Prospective, Randomized Trial

Carl S. Apstein, MD

From the Cardiac Muscle Research Laboratory, Whitaker Cardiovascular Institute, Boston University School of Medicine and Cardiology Section, Boston Medical Center, Boston, Mass.

Correspondence to Dr Carl S. Apstein, Director, Cardiac Muscle Research Laboratory, Boston University School of Medicine, 700 Albany St, Boston, MA 02118. E-mail capstein@bu.edu


Key Words: Editorials • glucose • insulin • potassium • myocardial infarction

A landmark study is reported in this issue of Circulation,1 continuing the rediscovery of glucose-insulin-potassium (GIK) treatment of acute myocardial infarction (AMI) that began in this journal last year with a meta-analysis and editorial.2 3 That meta-analysis considered all prior randomized trials of GIK for AMI (these were all done in the prethrombolytic era) and concluded that GIK had the potential to reduce AMI mortality by 28% to 48% depending on dosage and timing of therapy initiation relative to symptom onset. An accompanying editorial called for a modern large-scale trial of GIK in combination with thrombolysis for AMI. Such a prospective trial is now reported by the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group, and the results are dramatic.

The ECLA group reports the largest prospective, randomized trial of GIK for the treatment of AMI ever performed and the only such trial done in the era of thrombolytic therapy. They observed a remarkable 66% reduction (2P=0.008) in the relative in-hospital mortality risk when GIK was added to reperfusion (95% of those reperfused had thrombolysis, 5% had primary PTCA) relative to reperfusion alone; the absolute mortality risk decreased from 15.2% to 5.2%. Considering the relatively long average time from the onset of AMI symptoms until the start of treatment (10 to 11 hours), the magnitude of the mortality reduction was even more remarkable. Moreover, a survival benefit persisted during a 1-year follow-up period in the group that received high-dose GIK plus reperfusion as AMI treatment.

Adverse effects of the GIK . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
CirculationHome page
L. Wexler and J. S. Ingwall
Carl S. Apstein, MD: 1941-2005
Circulation, August 22, 2006; 114(8): 867 - 868.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Ma, H.-F. Zhang, L. Yu, Q.-J. Zhang, J. Li, J.-H. Huo, X. Li, W.-Y. Guo, H.-C. Wang, and F. Gao
Vasculoprotective effect of insulin in the ischemic/reperfused canine heart: Role of Akt-stimulated NO production
Cardiovasc Res, January 1, 2006; 69(1): 57 - 65.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Thiele, N. D. Price, T. D. Vo, and B. O. Palsson
Candidate Metabolic Network States in Human Mitochondria: IMPACT OF DIABETES, ISCHEMIA, AND DIET
J. Biol. Chem., March 25, 2005; 280(12): 11683 - 11695.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
K. P. Bouki, G. Pavlakis, and E. Papasteriadis
Management of Cardiogenic Shock Due to Acute Coronary Syndromes
Angiology, March 1, 2005; 56(2): 123 - 130.
[Abstract] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
T. Date, S. Mochizuki, A. J. Belanger, M. Yamakawa, Z. Luo, K. A. Vincent, S. H. Cheng, R. J. Gregory, and C. Jiang
Expression of constitutively stable hybrid hypoxia-inducible factor-1{alpha} protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury
Am J Physiol Cell Physiol, February 1, 2005; 288(2): C314 - C320.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. S. Ingwall and R. G. Weiss
Is the Failing Heart Energy Starved?: On Using Chemical Energy to Support Cardiac Function
Circ. Res., July 23, 2004; 95(2): 135 - 145.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. V. Simoes, S. Egert, S. Ziegler, M. Miyagawa, S. Reder, T. Lehner, N. Nguyen, M. J. Charron, and M. Schwaiger
Delayed response of insulin-stimulated fluorine-18 deoxyglucose uptake in glucose transporter-4-null mice hearts
J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1690 - 1697.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. A. Nikolaidis, S. Mankad, G. G. Sokos, G. Miske, A. Shah, D. Elahi, and R. P. Shannon
Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
Circulation, March 2, 2004; 109(8): 962 - 965.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch
Management of Diabetes and Hyperglycemia in Hospitals
Diabetes Care, February 1, 2004; 27(2): 553 - 591.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. S. Apstein
The benefits of glucose-insulin-potassium for acute myocardial infarction (and some concerns)
J. Am. Coll. Cardiol., September 3, 2003; 42(5): 792 - 795.
[Full Text] [PDF]


Home page
VASC ENDOVASCULAR SURGHome page
M. Aldemir, A. Gurel, H. Buyukbayram, and I. TaAyildiz
The Effects of Glucose-Insulin-Potassium Solution and BN 52021 in Intestinal Ischemia-Reperfusion Injury
Vascular and Endovascular Surgery, September 1, 2003; 37(5): 345 - 351.
[Abstract] [PDF]


Home page
Clin. DiabetesHome page
C. Abraira and W. Duckworth
The Need for Glycemic Trials in Type 2 Diabetes
Clin. Diabetes, July 1, 2003; 21(3): 107 - 111.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. N. Sack and D. M. Yellon
Insulin therapy as an adjunct toreperfusion after acute coronary ischemia: A proposed direct myocardial cell survival effect independent of metabolic modulation
J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1404 - 1407.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
S. Bruemmer-Smith, M. S. Avidan, B. Harris, S. Sudan, R. Sherwood, J. B. Desai, F. Sutherland, and J. Ponte
Glucose, insulin and potassium for heart protection during cardiac surgery
Br. J. Anaesth., April 1, 2002; 88(4): 489 - 495.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Ramanathan, K. Shirota, S. Morita, T. Nishimura, Y. Huang, and S. N. Hunyor
Glucose-insulin-potassium solution improves left ventricular mechanics in diabetes
Ann. Thorac. Surg., February 1, 2002; 73(2): 582 - 587.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Tian and E. D. Abel
Responses of GLUT4-Deficient Hearts to Ischemia Underscore the Importance of Glycolysis
Circulation, June 19, 2001; 103(24): 2961 - 2966.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
W. C. Duckworth, M. McCarren, and C. Abraira
Glucose Control and Cardiovascular Complications: The VA Diabetes Trial
Diabetes Care, May 1, 2001; 24(5): 942 - 945.
[Full Text]


Home page
QJMHome page
C.H. Davies
Revascularization for cardiogenic shock
QJM, February 1, 2001; 94(2): 57 - 67.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. F. Allard, R. B. Wambolt, S. L. Longnus, M. Grist, C. P. Lydell, H. L. Parsons, B. Rodrigues, J. L. Hall, W. C. Stanley, and G. P. Bondy
Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin
Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E487 - E493.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. C. Cave, J. S. Ingwall, J. Friedrich, R. Liao, K. W. Saupe, C. S. Apstein, and F. R. Eberli
ATP Synthesis During Low-Flow Ischemia : Influence of Increased Glycolytic Substrate
Circulation, May 2, 2000; 101(17): 2090 - 2096.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Sadaniantz
Glucose-Insulin-Potassium Use in Acute Myocardial Infarction
Circulation, November 30, 1999; 100 (22): e104 - e104.
[Full Text] [PDF]


Home page
CirculationHome page
T. O. Cheng
Glucose-Insulin-Potassium Use in Acute Myocardial Infarction
Circulation, November 30, 1999; 100 (22): e105 - e105.
[Full Text] [PDF]


Home page
NEJMHome page
T. J. Ryan
Early Revascularization in Cardiogenic Shock -- A Positive View of a Negative Trial
N. Engl. J. Med., August 26, 1999; 341(9): 687 - 688.
[Full Text]


Home page
Circ. Res.Home page
A. K. Jonassen, M. N. Sack, O. D. Mjos, and D. M. Yellon
Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling
Circ. Res., December 7, 2001; 89(12): 1191 - 1198.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Gao, E. Gao, T.-L. Yue, E. H. Ohlstein, B. L. Lopez, T. A. Christopher, and X.-L. Ma
Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial Ischemia-Reperfusion: The Roles of PI3-Kinase, Akt, and Endothelial Nitric Oxide Synthase Phosphorylation
Circulation, March 26, 2002; 105(12): 1497 - 1502.
[Abstract] [Full Text] [PDF]